Careers  |  Sign In  |  Register  |   Twitter

New Partnership Benefits Transplant Patients

Bloomberg News reports that “Novartis AG (NOVN) entered a collaboration with Regenerex LLC, gaining access to stem cell technology that may help kidney transplant patients avoid taking anti-rejection medicine for life.” The pills that patients take after a transplant surgery, prevent the new tissue from being attacked but also can damage the transplant, cause diabetes, heart disease, infections and cancer. The stem cell technology allows patients to stop taking these pills. “The technology may also be used in a number of inherited metabolic diseases with high unmet need such as sickle cell disease or metachromatic leukodystrophy.”

Read the article published by Bloomberg News.